Performance and predictors of minimal disease activity response in peripheral spondyloarthritis patients treated with adalimumab by Coates, LC, Abraham, S, Tillett, W, Mease, PJ, Ramiro, S, Wu, T, Wang, X, Pangan, AL, Song, I-H

Impact of initial therapy with upadacitinib or adalimumab on achievement of 48-week treatment goals in patients with rheumatoid arthritis: post hoc analysis of SELECT-COMPARE by Mysler, E, Tanaka, Y, Kavanaugh, A, Aletaha, D, Taylor, PC, Song, I-H, Shaw, T, Song, Y, DeMasi, R, Ali, M, Fleischmann, R

Efficacy and safety of upadacitinib in patients with active psoriatic arthritis and axial involvement: results from two phase 3 studies by Baraliakos, X, Ranza, R, Östör, A, Ciccia, F, Coates, LC, Rednic, S, Walsh, JA, Douglas, K, Gao, T, Kato, K, Song, I-H, Ganz, F, Deodhar, A